{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:01:25Z","timestamp":1775559685753,"version":"3.50.1"},"publisher-location":"Cham","reference-count":161,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030203009","type":"print"},{"value":"9783030203016","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-030-20301-6_8","type":"book-chapter","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T12:03:54Z","timestamp":1566907434000},"page":"131-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Therapeutic Options for Metastatic Breast Cancer"],"prefix":"10.1007","author":[{"given":"Manpreet","family":"Sambi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bessi","family":"Qorri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Harless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron R.","family":"Szewczuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"8_CR1","unstructured":"Canadian Cancer Society\u2019s Advisory Committee on Cancer Statistics (2017)"},{"issue":"3","key":"8_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12282-011-0276-3","volume":"19","author":"YC Cheng","year":"2012","unstructured":"Cheng YC, Ueno NT (2012) Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer 19(3):191\u2013199","journal-title":"Breast Cancer"},{"issue":"6024","key":"8_CR3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559","journal-title":"Science"},{"issue":"10","key":"8_CR4","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-07-2938","volume":"68","author":"TT Onder","year":"2008","unstructured":"Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68(10):3645","journal-title":"Cancer Res"},{"issue":"35","key":"8_CR5","doi-asserted-by":"publisher","first-page":"15449","DOI":"10.1073\/pnas.1004900107","volume":"107","author":"JH Taube","year":"2010","unstructured":"Taube JH, Herschkowitz JI, Komurov K et al (2010) Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci 107(35):15449\u201315454","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"8_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.2217\/fon.11.112","volume":"7","author":"LR Patel","year":"2011","unstructured":"Patel LR, Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS (2011) Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol 7(11):1285\u20131297","journal-title":"Future Oncol"},{"issue":"13","key":"8_CR7","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1242\/jcs.069443","volume":"123","author":"K Stoletov","year":"2010","unstructured":"Stoletov K, Kato H, Zardouzian E et al (2010) Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 123(13):2332\u20132341","journal-title":"J Cell Sci"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature06188","volume":"449","author":"AE Karnoub","year":"2007","unstructured":"Karnoub AE, Dash AB, Vo AP et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557\u2013563","journal-title":"Nature"},{"issue":"6","key":"8_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","volume":"14","author":"J Yang","year":"2008","unstructured":"Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14(6):818\u2013829","journal-title":"Dev Cell"},{"issue":"11","key":"8_CR10","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/ijc.26031","volume":"128","author":"RR Langley","year":"2011","unstructured":"Langley RR, Fidler IJ (2011) The seed and soil hypothesis revisited\u2014the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128(11):2527\u20132535","journal-title":"Int J Cancer"},{"issue":"2","key":"8_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/scbi.2001.0417","volume":"12","author":"CD Roskelley","year":"2002","unstructured":"Roskelley CD, Bissell MJ (2002) The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol 12(2):97\u2013104","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"8_CR12","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.cell.2012.11.024","volume":"151","author":"V Luga","year":"2012","unstructured":"Luga V, Zhang L, Viloria-Petit Alicia M et al (2012) Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 151(7):1542\u20131556","journal-title":"Cell"},{"issue":"9","key":"8_CR13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/sj.leu.2404296","volume":"20","author":"J Ratajczak","year":"2006","unstructured":"Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ (2006) Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20(9):1487\u20131495","journal-title":"Leukemia"},{"issue":"4","key":"8_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00109-013-1020-6","volume":"91","author":"C Kahlert","year":"2013","unstructured":"Kahlert C, Kalluri R (2013) Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med 91(4):431\u2013437","journal-title":"J Mol Med"},{"issue":"7","key":"8_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/jnci\/djq029","volume":"102","author":"O Pagani","year":"2010","unstructured":"Pagani O, Senkus E, Wood W et al (2010) International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? JNCI J Natl Cancer Inst 102(7):456\u2013463","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"9","key":"8_CR16","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1245\/ASO.2004.01.007","volume":"11","author":"G Vlastos","year":"2004","unstructured":"Vlastos G, Smith DL, Singletary SE et al (2004) Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 11(9):869\u2013874","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"8_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/ejso.1999.0761","volume":"26","author":"M Pocard","year":"2000","unstructured":"Pocard M, Pouillart P, Asselain B, Salmon RJ (2000) Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol (EJSO) 26(2):155\u2013159","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"1","key":"8_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-009-0670-0","volume":"120","author":"ACV Jetske Ruiterkamp","year":"2009","unstructured":"Jetske Ruiterkamp ACV, Bosscha K, Vivianne CG, Tjan-Heijnen MFE (2009) Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat 120(1):9\u201316","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"8_CR19","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1200\/JCO.2005.04.2226","volume":"24","author":"E Rapiti","year":"2006","unstructured":"Rapiti E, Verkooijen HM, Vlastos G et al (2006) Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 24(18):2743\u20132749","journal-title":"J Clin Oncol"},{"issue":"8","key":"8_CR20","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1245\/s10434-007-9438-0","volume":"14","author":"J Gnerlich","year":"2007","unstructured":"Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988\u20132003 SEER data. Ann Surg Oncol 14(8):2187\u20132194","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"8_CR21","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1245\/s10434-007-9527-0","volume":"14","author":"RC Fields","year":"2007","unstructured":"Fields RC, Jeffe DB, Trinkaus K et al (2007) Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 14(12):3345\u20133351","journal-title":"Ann Surg Oncol"},{"key":"8_CR22","doi-asserted-by":"crossref","unstructured":"Badwe R, Parmar B (2013) Surgical removal of primary breast tumor and axillary lymph nodes at first presentation in women with metastatic breast cancer; a prospective randomized controlled trial. Breast Cancer Symposium. San Antonio","DOI":"10.1158\/0008-5472.SABCS13-S2-02"},{"key":"8_CR23","unstructured":"Morrow M, Burstein H, Harris JR (2015) Malignant tumors of the breast. In: Cancer: principles and practice of oncology, 10th edn. Philadelphia, Pa, Lippincott Williams & Wilkins"},{"issue":"17","key":"8_CR24","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1001\/jama.2012.3481","volume":"307","author":"GL Smith","year":"2012","unstructured":"Smith GL, Xu Y, Buchholz TA et al (2012) Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA 307(17):1827\u20131837","journal-title":"JAMA"},{"issue":"6","key":"8_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1634\/theoncologist.2012-0438","volume":"18","author":"S Dawood","year":"2013","unstructured":"Dawood S, Gonzalez-Angulo AM (2013) Progress in the biological understanding and management of breast cancer-associated central nervous system metastases. Oncologist 18(6):675\u2013684","journal-title":"Oncologist"},{"issue":"5","key":"8_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000333115","volume":"6","author":"K Dellas","year":"2011","unstructured":"Dellas K (2011) Does radiotherapy have curative potential in metastatic patients? The concept of local therapy in oligometastatic breast cancer. Breast Care 6(5):363\u2013368","journal-title":"Breast Care"},{"issue":"9","key":"8_CR27","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","volume":"14","author":"R Paridaens","year":"2003","unstructured":"Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14(9):1391\u20131398","journal-title":"Ann Oncol"},{"issue":"2","key":"8_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.hoc.2007.03.001","volume":"21","author":"EL Mayer","year":"2007","unstructured":"Mayer EL, Burstein HJ (2007) Chemotherapy for metastatic breast cancer. Hematol Oncol Clin N Am 21(2):257\u2013272","journal-title":"Hematol Oncol Clin N Am"},{"issue":"1","key":"8_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/annonc\/mdj029","volume":"17","author":"L Mastro Del","year":"2006","unstructured":"Del Mastro L, Catzeddu T, Boni L et al (2006) Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 17(1):74\u201378","journal-title":"Ann Oncol"},{"issue":"3","key":"8_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1200\/JCO.2002.20.3.751","volume":"20","author":"J Geisler","year":"2002","unstructured":"Geisler J, Haynes B, Anker G, Dowsett M, L\u00f8nning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20(3):751\u2013757","journal-title":"J Clin Oncol"},{"issue":"8","key":"8_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/00001813-200009000-00002","volume":"11","author":"A Buzdar","year":"2000","unstructured":"Buzdar A (2000) Exemestane in advanced breast cancer. Anti-Cancer Drugs 11(8):609\u2013616","journal-title":"Anti-Cancer Drugs"},{"issue":"6","key":"8_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1159\/000090985","volume":"69","author":"G Bertelli","year":"2005","unstructured":"Bertelli G, Garrone O, Merlano M et al (2005) Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 69(6):471\u2013477","journal-title":"Oncology"},{"issue":"5","key":"8_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2174\/187152009788451833","volume":"9","author":"J Peng","year":"2009","unstructured":"Peng J, Sengupta S, Jordan VC (2009) Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anti-Cancer Agents Med Chem 9(5):481\u2013499","journal-title":"Anti-Cancer Agents Med Chem"},{"issue":"1","key":"8_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.beem.2003.08.002","volume":"18","author":"SJ Howell","year":"2004","unstructured":"Howell SJ, Johnston SRD, Howell A (2004) The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 18(1):47\u201366","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"8_CR35","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2014","unstructured":"Francis PA, Regan MM, Fleming GF et al (2014) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436\u2013446","journal-title":"N Engl J Med"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1016\/j.breast.2015.07.027","volume":"24","author":"A Mathew","year":"2015","unstructured":"Mathew A, Davidson NE (2015) Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast 24:S120\u2013S125","journal-title":"Breast"},{"issue":"14","key":"8_CR37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJM199810013391407","volume":"339","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN (1998) Treatment of breast cancer. N Engl J Med 339(14):974\u2013984","journal-title":"N Engl J Med"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4137\/BCBCR.S32783","volume":"10","author":"SB Zeichner","year":"2016","unstructured":"Zeichner SB, Terawaki H, Gogineni K (2016) A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer Basic Clin Res 10:25\u201336","journal-title":"Breast Cancer Basic Clin Res"},{"issue":"3","key":"8_CR39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"10","author":"J O\u2019Shaughnessy","year":"2005","unstructured":"O\u2019Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(3):20\u201329","journal-title":"Oncologist"},{"issue":"3","key":"8_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5306\/wjco.v5.i3.529","volume":"5","author":"JA Crozier","year":"2014","unstructured":"Crozier JA, Swaika A, Moreno-Aspitia A (2014) Adjuvant chemotherapy in breast cancer: to use or not to use, the anthracyclines. World J Clin Oncol 5(3):529\u2013538","journal-title":"World J Clin Oncol"},{"issue":"3","key":"8_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"MER O\u2019Brien","year":"2004","unstructured":"O\u2019Brien MER, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15(3):440\u2013449","journal-title":"Ann Oncol"},{"issue":"2","key":"8_CR42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17(2):485\u2013485","journal-title":"J Clin Oncol"},{"issue":"11","key":"8_CR43","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792","journal-title":"N Engl J Med"},{"issue":"3","key":"8_CR44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719\u2013726","journal-title":"J Clin Oncol"},{"issue":"6","key":"8_CR45","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1200\/JCO.2002.20.6.1467","volume":"20","author":"A Lipton","year":"2002","unstructured":"Lipton A, Ali SM, Leitzel K et al (2002) Elevated serum HER-2\/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20(6):1467\u20131472","journal-title":"J Clin Oncol"},{"issue":"33","key":"8_CR46","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor\u2013positive metastatic breast cancer. J Clin Oncol 27(33):5538\u20135546","journal-title":"J Clin Oncol"},{"issue":"25","key":"8_CR47","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson cancer center experience. J Clin Oncol 24(25):4107\u20134115","journal-title":"J Clin Oncol"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","volume":"30","author":"MA Cobleigh","year":"2003","unstructured":"Cobleigh MA, Langmuir VK, Sledge GW et al (2003) A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117\u2013124","journal-title":"Semin Oncol"},{"issue":"1","key":"8_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-009-0727-0","volume":"122","author":"A Valachis","year":"2010","unstructured":"Valachis A, Polyzos NP, Patsopoulos N\u0391, Georgoulias V, Mavroudis D, Mauri D (2010) Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 122(1):1\u20137","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"8_CR50","first-page":"00016","volume":"1","author":"M Sambi","year":"2017","unstructured":"Sambi M, Qorri B, Malardier-Jugroot C, Szewczuk M (2017) Advancements in polymer science: \u2018Smart\u2019 drug delivery systems for the treatment of cancer. MOJ Polym Sci 1(3):00016","journal-title":"MOJ Polym Sci"},{"issue":"11","key":"8_CR51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","volume":"30","author":"Y Malam","year":"2009","unstructured":"Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30(11):592\u2013599","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"8_CR52","first-page":"57","volume":"26","author":"B Haley","year":"2008","unstructured":"Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol Semin Original Inv 26(1):57\u201364","journal-title":"Urol Oncol Semin Original Inv"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bpc.2016.04.002","volume":"214\u2013215","author":"X Li","year":"2016","unstructured":"Li X, McTaggart M, Malardier-Jugroot C (2016) Synthesis and characterization of a pH responsive folic acid functionalized polymeric drug delivery system. Biophys Chem 214\u2013215:17\u201326","journal-title":"Biophys Chem"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.2147\/DDDT.S123386","volume":"10","author":"X Li","year":"2016","unstructured":"Li X, Szewczuk MR, Malardier-Jugroot C (2016) Folic acid-conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platform. Drug Des Devel Ther 10:4101\u20134110","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"8_CR55","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.biomaterials.2011.09.064","volume":"33","author":"DN Heo","year":"2012","unstructured":"Heo DN, Yang DH, Moon H-J et al (2012) Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials 33(3):856\u2013866","journal-title":"Biomaterials"},{"issue":"12","key":"8_CR56","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1021\/ar800150g","volume":"41","author":"S Lal","year":"2008","unstructured":"Lal S, Clare SE, Halas NJ (2008) Nanoshell-enabled photothermal cancer therapy: impending clinical impact. Acc Chem Res 41(12):1842\u20131851","journal-title":"Acc Chem Res"},{"issue":"19","key":"8_CR57","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19):4265\u20134274","journal-title":"J Clin Oncol"},{"issue":"33","key":"8_CR58","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","volume":"27","author":"B Kaufman","year":"2009","unstructured":"Kaufman B, Mackey JR, Clemens MR et al (2009) Trastuzumab plus anastrozole aersus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2\u2013positive, hormone receptor\u2013positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27(33):5529\u20135537","journal-title":"J Clin Oncol"},{"issue":"10","key":"8_CR59","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Di\u00e9ras V, Glaspy J et\u00a0al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2\u2013negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29(10):1252\u20131260","journal-title":"J Clin Oncol"},{"issue":"20","key":"8_CR60","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2\u2013negative metastatic breast cancer. J Clin Oncol 28(20):3239\u20133247","journal-title":"J Clin Oncol"},{"issue":"7","key":"8_CR61","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc3950","volume":"15","author":"FJ Sanchez-Rivera","year":"2015","unstructured":"Sanchez-Rivera FJ, Jacks T (2015) Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 15(7):387\u2013395","journal-title":"Nat Rev Cancer"},{"key":"8_CR62","doi-asserted-by":"publisher","first-page":"16025","DOI":"10.1038\/celldisc.2016.25","volume":"2","author":"JH Lee","year":"2016","unstructured":"Lee JH, Zhao XM, Yoon I et al (2016) Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. Cell Discov 2:16025","journal-title":"Cell Discov"},{"issue":"1","key":"8_CR63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-011-1925-0","volume":"134","author":"CY Wang","year":"2012","unstructured":"Wang CY, Uray IP, Mazumdar A, Mayer JA, Brown PH (2012) SLC22A5\/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE). Breast Cancer Res Treat 134(1):101\u2013115","journal-title":"Breast Cancer Res Treat"},{"key":"8_CR64","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1752-0509-5-121","volume":"5","author":"LM Tran","year":"2011","unstructured":"Tran LM, Zhang B, Zhang Z et al (2011) Inferring causal genomic alterations in breast cancer using gene expression data. BMC Syst Biol 5:121","journal-title":"BMC Syst Biol"},{"issue":"35","key":"8_CR65","doi-asserted-by":"publisher","first-page":"13033","DOI":"10.1073\/pnas.0801610105","volume":"105","author":"NG Zhang","year":"2008","unstructured":"Zhang NG, Ge GQ, Meyer R et al (2008) Overexpression of Separase induces aneuploidy and mammary tumorigenesis. Proc Natl Acad Sci U S A 105(35):13033\u201313038","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"8_CR66","doi-asserted-by":"publisher","first-page":"e1002201","DOI":"10.1371\/journal.pmed.1002201","volume":"13","author":"C Lefebvre","year":"2016","unstructured":"Lefebvre C, Bachelot T, Filleron T et al (2016) Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med 13(12):e1002201","journal-title":"PLoS Med"},{"issue":"6","key":"8_CR67","doi-asserted-by":"publisher","first-page":"e99306","DOI":"10.1371\/journal.pone.0099306","volume":"9","author":"X Bai","year":"2014","unstructured":"Bai X, Zhang E, Ye H et al (2014) PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS One 9(6):e99306","journal-title":"PLoS One"},{"issue":"20","key":"8_CR68","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"8","key":"8_CR69","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1080\/03007995.2017.1325730","volume":"33","author":"C Chirila","year":"2017","unstructured":"Chirila C, Mitra D, Colosia A et al (2017) Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced\/metastatic breast cancer: network meta-analysis. Curr Med Res Opin 33(8):1457\u20131466","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"8_CR70","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1634\/theoncologist.9-4-361","volume":"9","author":"C Osborne","year":"2004","unstructured":"Osborne C, Wilson P, Tripathy D (2004) Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9(4):361\u2013377","journal-title":"Oncologist"},{"issue":"7","key":"8_CR71","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2015.067","volume":"26","author":"SH Yao","year":"2015","unstructured":"Yao SH, He ZY, Chen C (2015) CRISPR\/Cas9-mediated genome editing of epigenetic factors for cancer therapy. Hum Gene Ther 26(7):463\u2013471","journal-title":"Hum Gene Ther"},{"issue":"4","key":"8_CR72","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1101\/gad.184341.111","volume":"26","author":"JJ Trowbridge","year":"2012","unstructured":"Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH (2012) Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 26(4):344\u2013349","journal-title":"Genes Dev"},{"issue":"6","key":"8_CR73","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.bcp.2004.04.030","volume":"68","author":"M Szyf","year":"2004","unstructured":"Szyf M, Pakneshan P, Rabbani SA (2004) DNA methylation and breast cancer. Biochem Pharmacol 68(6):1187\u20131197","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"8_CR74","first-page":"1811","volume":"10","author":"XC Hu","year":"2003","unstructured":"Hu XC, Wong IH, Chow LW (2003) Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Oncol Rep 10(6):1811\u20131815","journal-title":"Oncol Rep"},{"issue":"4","key":"8_CR75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nbt.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347\u2013355","journal-title":"Nat Biotechnol"},{"issue":"5962","key":"8_CR76","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.1179555","volume":"327","author":"P Horvath","year":"2010","unstructured":"Horvath P, Barrangou R (2010) CRISPR\/Cas, the immune system of bacteria and archaea. Science 327(5962):167\u2013170","journal-title":"Science"},{"issue":"7522","key":"8_CR77","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature13589","volume":"514","author":"W Xue","year":"2014","unstructured":"Xue W, Chen S, Yin H et al (2014) CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514(7522):380\u2013384","journal-title":"Nature"},{"issue":"4","key":"8_CR78","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/bcr1530","volume":"8","author":"A Fantozzi","year":"2006","unstructured":"Fantozzi A, Christofori G (2006) Mouse models of breast cancer metastasis. Breast Cancer Res BCR 8(4):212","journal-title":"Breast Cancer Res BCR"},{"issue":"1","key":"8_CR79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE Visser de","year":"2006","unstructured":"de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6(1):24\u201337","journal-title":"Nat Rev Cancer"},{"key":"8_CR80","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1155\/2014\/149185","volume":"2014","author":"G Landskron","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:19","journal-title":"J Immunol Res"},{"issue":"4","key":"8_CR81","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","volume":"102","author":"Y Wu","year":"2010","unstructured":"Wu Y, Zhou BP (2010) TNF-\u03b1\/NF-\u03baB\/Snail pathway in cancer cell migration and invasion. Br J Cancer 102(4):639\u2013644","journal-title":"Br J Cancer"},{"issue":"1","key":"8_CR82","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41598-017-01644-0","volume":"7","author":"X Zhao","year":"2017","unstructured":"Zhao X, Xu Z, Li H (2017) NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis. Sci Rep 7(1):1875","journal-title":"Sci Rep"},{"issue":"1","key":"8_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arabjc.2011.07.020","volume":"6","author":"N Kumar","year":"2013","unstructured":"Kumar N, Drabu S, Mondal SC (2013) NSAID\u2019s and selectively COX-2 inhibitors as potential chemoprotective agents against cancer: 1st Cancer Update. Arab J Chem 6(1):1\u201323","journal-title":"Arab J Chem"},{"issue":"1","key":"8_CR84","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/s12885-016-2692-4","volume":"16","author":"T Dierssen-Sotos","year":"2016","unstructured":"Dierssen-Sotos T, G\u00f3mez-Acebo I, de Pedro M et al (2016) Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: the Spanish Multi-Case-control (MCC) study. BMC Cancer 16(1):660","journal-title":"BMC Cancer"},{"issue":"6282","key":"8_CR85","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","volume":"352","author":"EB Rankin","year":"2016","unstructured":"Rankin EB, Giaccia AJ (2016) Hypoxic control of metastasis. Science (New York, NY) 352(6282):175\u2013180","journal-title":"Science (New York, NY)"},{"issue":"11","key":"8_CR86","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2217\/fon.13.92","volume":"9","author":"DM Gilkes","year":"2013","unstructured":"Gilkes DM, Semenza GL (2013) Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol (London, England) 9(11):1623\u20131636","journal-title":"Future Oncol (London, England)"},{"issue":"8","key":"8_CR87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/gm271","volume":"3","author":"E Favaro","year":"2011","unstructured":"Favaro E, Lord S, Harris AL, Buffa FM (2011) Gene expression and hypoxia in breast cancer. Genome Med 3(8):55\u201355","journal-title":"Genome Med"},{"key":"8_CR88","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","volume":"3","author":"B Muz","year":"2015","unstructured":"Muz B, de la Puente P, Azab F, Azab AK (2015) The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 3:83\u201392","journal-title":"Hypoxia"},{"issue":"39","key":"8_CR89","doi-asserted-by":"publisher","first-page":"16369","DOI":"10.1073\/pnas.1113483108","volume":"108","author":"CC-L Wong","year":"2011","unstructured":"Wong CC-L, Gilkes DM, Zhang H et al (2011) Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci 108(39):16369\u201316374","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"8_CR90","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1074\/mcp.M900381-MCP200","volume":"9","author":"JE Park","year":"2010","unstructured":"Park JE, Tan HS, Datta A et al (2010) Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 9(6):1085\u20131099","journal-title":"Mol Cell Proteomics"},{"issue":"9a","key":"8_CR91","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1111\/j.1582-4934.2009.00876.x","volume":"13","author":"B Onnis","year":"2009","unstructured":"Onnis B, Rapisarda A, Melillo G (2009) Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 13(9a):2780\u20132786","journal-title":"J Cell Mol Med"},{"issue":"5","key":"8_CR92","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4155\/fmc.4113.4117","volume":"5","author":"SK Burroughs","year":"2013","unstructured":"Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B (2013) Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem 5(5):553\u2013572. https:\/\/doi.org\/10.4155\/fmc.4113.4117","journal-title":"Future Med Chem"},{"issue":"5706","key":"8_CR93","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58\u201362","journal-title":"Science"},{"issue":"17","key":"8_CR94","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK (2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31(17):2205\u20132218","journal-title":"J Clin Oncol"},{"issue":"3","key":"8_CR95","doi-asserted-by":"publisher","first-page":"a006486","DOI":"10.1101\/cshperspect.a006486","volume":"2","author":"S Goel","year":"2012","unstructured":"Goel S, Wong AH, Jain RK (2012) Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2(3):a006486","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"8_CR96","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr2642","volume":"12","author":"DL Nielsen","year":"2010","unstructured":"Nielsen DL, Andersson M, Andersen JL, Kamby C (2010) Antiangiogenic therapy for breast cancer. Breast Cancer Res BCR 12(5):209","journal-title":"Breast Cancer Res BCR"},{"issue":"7070","key":"8_CR97","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967\u2013974","journal-title":"Nature"},{"key":"8_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-2-1","volume":"2","author":"P Zhang","year":"2003","unstructured":"Zhang P, Gao WY, Turner S, Ducatman BS (2003) Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2:1","journal-title":"Mol Cancer"},{"issue":"15_suppl","key":"8_CR99","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/jco.2010.28.15_suppl.1021","volume":"28","author":"A. Brufsky","year":"2010","unstructured":"Brufsky A, Rivera RR, Hurvitz SA et al (2010) Progression-free survival. (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 28:15_suppl, 1021","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"8_CR100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"B-Z Qian","year":"2010","unstructured":"Qian B-Z, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39\u201351","journal-title":"Cell"},{"issue":"1","key":"8_CR101","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"JW Pollard","year":"2004","unstructured":"Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71\u201378","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"8_CR102","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cell.2006.01.007","volume":"124","author":"J Condeelis","year":"2006","unstructured":"Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2):263\u2013266","journal-title":"Cell"},{"issue":"45","key":"8_CR103","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45):5904\u20135912","journal-title":"Oncogene"},{"issue":"10","key":"8_CR104","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, Akkari L, Schuhmacher AJ et al (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19(10):1264\u20131272","journal-title":"Nat Med"},{"issue":"1\u20132","key":"8_CR105","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10555-012-9415-3","volume":"32","author":"Y Mao","year":"2013","unstructured":"Mao Y, Keller ET, Garfield DH, Shen K, Wang J (2013) Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 32(1\u20132):303\u2013315","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"8_CR106","doi-asserted-by":"publisher","first-page":"e7965","DOI":"10.1371\/journal.pone.0007965","volume":"4","author":"D Liao","year":"2009","unstructured":"Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA (2009) Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4(11):e7965","journal-title":"PLoS One"},{"issue":"2","key":"8_CR107","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jconrel.2010.05.015","volume":"147","author":"Y-L Hu","year":"2010","unstructured":"Hu Y-L, Fu Y-H, Tabata Y, Gao J-Q (2010) Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release 147(2):154\u2013162","journal-title":"J Control Release"},{"issue":"21","key":"8_CR108","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/jnci\/djh299","volume":"96","author":"M Studeny","year":"2004","unstructured":"Studeny M, Marini FC, Dembinski JL et al (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. JNCI J Natl Cancer Inst 96(21):1593\u20131603","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"8_CR109","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2014.09.051","volume":"159","author":"C Boelens Mirjam","year":"2014","unstructured":"Boelens Mirjam C, Wu Tony J, Nabet Barzin Y et al (2014) Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 159(3):499\u2013513","journal-title":"Cell"},{"issue":"3","key":"8_CR110","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.addr.2012.08.007","volume":"65","author":"A Suetsugu","year":"2013","unstructured":"Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM (2013) Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev 65(3):383\u2013390","journal-title":"Adv Drug Deliv Rev"},{"issue":"22","key":"8_CR111","doi-asserted-by":"publisher","first-page":"20083","DOI":"10.1074\/jbc.M301642200","volume":"278","author":"A Savina","year":"2003","unstructured":"Savina A, Furl\u00e1n M, Vidal M, Colombo MI (2003) Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 278(22):20083\u201320090","journal-title":"J Biol Chem"},{"issue":"1","key":"8_CR112","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/1471-2407-12-421","volume":"12","author":"HW King","year":"2012","unstructured":"King HW, Michael MZ, Gleadle JM (2012) Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 12(1):421","journal-title":"BMC Cancer"},{"key":"8_CR113","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/199079a0","volume":"199","author":"WR Bruce","year":"1963","unstructured":"Bruce WR, Van Der Gaag H (1963) A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199:79\u201380","journal-title":"Nature"},{"issue":"7","key":"8_CR114","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1073\/pnas.0830967100","volume":"100","author":"JE Dick","year":"2003","unstructured":"Dick JE (2003) Breast cancer stem cells revealed. Proc Natl Acad Sci U S A 100(7):3547\u20133549","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"8_CR115","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","volume":"67","author":"C Li","year":"2007","unstructured":"Li C, Heidt DG, Dalerba P et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030\u20131037","journal-title":"Cancer Res"},{"issue":"24","key":"8_CR116","doi-asserted-by":"publisher","first-page":"10158","DOI":"10.1073\/pnas.0703478104","volume":"104","author":"P Dalerba","year":"2007","unstructured":"Dalerba P, Dylla SJ, Park IK et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 104(24):10158\u201310163","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"8_CR117","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7):3983\u20133988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR118","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.pharmthera.2016.02.008","volume":"160","author":"J Zhao","year":"2016","unstructured":"Zhao J (2016) Cancer stem cells and chemoresistance: the smartest survives the raid. Pharmacol Ther 160:145\u2013158","journal-title":"Pharmacol Ther"},{"issue":"1","key":"8_CR119","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2001-1326-2-3","volume":"2","author":"LN Abdullah","year":"2013","unstructured":"Abdullah LN, Chow EK (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2(1):3","journal-title":"Clin Transl Med"},{"issue":"2","key":"8_CR120","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275\u2013292","journal-title":"J Pathol"},{"issue":"1","key":"8_CR121","doi-asserted-by":"publisher","first-page":"R6","DOI":"10.1186\/bcr3087","volume":"14","author":"LP Schwab","year":"2012","unstructured":"Schwab LP, Peacock DL, Majumdar D et al (2012) Hypoxia-inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res BCR 14(1):R6","journal-title":"Breast Cancer Res BCR"},{"issue":"7408","key":"8_CR122","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson TR, Fridlyand J, Yan Y et al (2012) Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487(7408):505\u2013509","journal-title":"Nature"},{"issue":"36","key":"8_CR123","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1038\/sj.onc.1203768","volume":"19","author":"NM Patel","year":"2000","unstructured":"Patel NM, Nozaki S, Shortle NH et al (2000) Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19(36):4159\u20134169","journal-title":"Oncogene"},{"issue":"73","key":"8_CR124","doi-asserted-by":"publisher","first-page":"73ra21","DOI":"10.1126\/scitranslmed.3001713","volume":"3","author":"EK Chow","year":"2011","unstructured":"Chow EK, Zhang XQ, Chen M et al (2011) Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci Transl Med 3(73):73ra21","journal-title":"Sci Transl Med"},{"key":"8_CR125","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/nano8080588","volume":"8","author":"X Li","year":"2018","unstructured":"Li X, Sambi M, DeCarlo A et al (2018) Functionalized folic acid-conjugated amphiphilic alternating copolymer actively targets 3D multicellular tumour spheroids and delivers the hydrophobic drug to the inner core. Nanomaterials 8: 588\u2013608","journal-title":"Nanomaterials"},{"issue":"5","key":"8_CR126","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ijc.22811","volume":"121","author":"LC Hartmann","year":"2007","unstructured":"Hartmann LC, Keeney GL, Lingle WL et al (2007) Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121(5):938\u2013942","journal-title":"Int J Cancer"},{"issue":"4","key":"8_CR127","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"issue":"2 Pt 1","key":"8_CR128","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria S, Kawashima N, Yang AM et al (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 11(2 Pt 1):728\u2013734","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"8_CR129","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"A Elsas van","year":"1999","unstructured":"van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3):355\u2013366","journal-title":"J Exp Med"},{"issue":"7","key":"8_CR130","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027\u20131034","journal-title":"J Exp Med"},{"issue":"2","key":"8_CR131","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141\u2013151","journal-title":"Immunity"},{"issue":"4","key":"8_CR132","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F et al (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361\u2013370","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"8_CR133","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399\u2013416","journal-title":"Nat Rev Clin Oncol"},{"key":"8_CR134","doi-asserted-by":"publisher","first-page":"C14","DOI":"10.1007\/BF01972706","volume":"39 Spec No","author":"JE Meats","year":"1993","unstructured":"Meats JE, Steele L, Bowen JG (1993) Identification of phospholipase D (PLD) activity in mouse peritoneal macrophages. Agents Actions 39 Spec No:C14\u2013C16","journal-title":"Agents Actions"},{"issue":"11","key":"8_CR135","doi-asserted-by":"publisher","first-page":"e0166553","DOI":"10.1371\/journal.pone.0166553","volume":"11","author":"KM Henkels","year":"2016","unstructured":"Henkels KM, Muppani NR, Gomez-Cambronero J (2016) PLD-specific small-molecule inhibitors decrease tumor-associated macrophages and neutrophils infiltration in breast tumors and lung and liver metastases. PLoS One 11(11):e0166553","journal-title":"PLoS One"},{"key":"8_CR136","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-0-387-74039-3_9","volume":"608","author":"M Tan","year":"2007","unstructured":"Tan M, Yu D (2007) Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol 608:119\u2013129","journal-title":"Adv Exp Med Biol"},{"issue":"4905","key":"8_CR137","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712","journal-title":"Science"},{"issue":"1","key":"8_CR138","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4161\/cam.4.1.10497","volume":"4","author":"Y Wang","year":"2010","unstructured":"Wang Y (2010) Breast cancer metastasis driven by ErbB2 and 14-3-3zeta: a division of labor. Cell Adhes Migr 4(1):7\u20139","journal-title":"Cell Adhes Migr"},{"issue":"7\u20139","key":"8_CR139","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1387\/ijdb.113396se","volume":"55","author":"SA Eccles","year":"2011","unstructured":"Eccles SA (2011) The epidermal growth factor receptor\/Erb-B\/HER family in normal and malignant breast biology. Int J Dev Biol 55(7\u20139):685\u2013696","journal-title":"Int J Dev Biol"},{"issue":"2","key":"8_CR140","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molonc.2012.02.004","volume":"6","author":"S Hoelder","year":"2012","unstructured":"Hoelder S, Clarke PA, Workman P (2012) Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 6(2):155\u2013176","journal-title":"Mol Oncol"},{"issue":"4","key":"8_CR141","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.18632\/oncotarget.12878","volume":"8","author":"D Li","year":"2017","unstructured":"Li D, Marchenko ND (2017) ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells. Oncotarget 8(4):5823\u20135833","journal-title":"Oncotarget"},{"issue":"4","key":"8_CR142","first-page":"215","volume":"15","author":"KN Dziadkowiec","year":"2016","unstructured":"Dziadkowiec KN, Gasiorowska E, Nowak-Markwitz E, Jankowska A (2016) PARP inhibitors: review of mechanisms of action and BRCA1\/2 mutation targeting. Prz Menopauzalny 15(4):215\u2013219","journal-title":"Prz Menopauzalny"},{"issue":"5","key":"8_CR143","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1073\/pnas.95.5.2302","volume":"95","author":"T Ouchi","year":"1998","unstructured":"Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H (1998) BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A 95(5):2302\u20132306","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8_CR144","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","volume":"24","author":"J Morales","year":"2014","unstructured":"Morales J, Li L, Fattah FJ et al (2014) Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 24(1):15\u201328","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"8_CR145","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bmb\/ldp005","volume":"89","author":"AJ Chalmers","year":"2009","unstructured":"Chalmers AJ (2009) The potential role and application of PARP inhibitors in cancer treatment. Br Med Bull 89:23\u201340","journal-title":"Br Med Bull"},{"issue":"3","key":"8_CR146","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa1011418","volume":"364","author":"J O\u2019Shaughnessy","year":"2011","unstructured":"O\u2019Shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205\u2013214","journal-title":"N Engl J Med"},{"issue":"21","key":"8_CR147","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588\u20135599","journal-title":"Cancer Res"},{"issue":"12","key":"8_CR148","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.cellsig.2013.08.008","volume":"25","author":"AM Gilmour","year":"2013","unstructured":"Gilmour AM, Abdulkhalek S, Cheng TS et al (2013) A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. Cell Signal25(12):2587\u20132603","journal-title":"Cell Signal"},{"key":"8_CR149","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.cellsig.2009.09.038","volume":"22","author":"SR Amith","year":"2010","unstructured":"Amith SR, Jayanth P, Franchuk S et al (2010) Neu1 desialylation of sialyl \u03b1-2,3-linked \u03b2-galactosyl residues of TOLL-like is essential for receptor activation and cellular signaling. Cellular Signalling 22: 314\u2013324","journal-title":"Cellular Signalling"},{"issue":"42","key":"8_CR150","doi-asserted-by":"publisher","first-page":"36532","DOI":"10.1074\/jbc.M111.237578","volume":"286","author":"Samar Abdulkhalek","year":"2011","unstructured":"Abdulkhalek S, Amith SR, Franchuk SL et al (2011) Neu1 sialidase and matrix metalloproteinase-9 cross-talk Is essential for Toll-like receptor activation and cellular signaling. J Biol Chem 286 (42): 36532\u201336549","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"8_CR151","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.cellsig.2012.06.016","volume":"24","author":"Samar Abdulkhalek","year":"2012","unstructured":"Abdulkhalek S, Guo M, Amith SR et al (2012) G-protein coupled receptor agonists mediate Neu1 sialidase and matrix metalloproteinase-9 cross-talk to induce transactivation of TOLL-like receptors and cellular signaling. Cellular Signalling 24: 2035\u20132042","journal-title":"Cellular Signalling"},{"key":"8_CR152","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/j.cellsig.2013.06.010","volume":"25","author":"S Abdulkhalek","year":"2013","unstructured":"Abdulkhalek S, Szewczuk MR (2013) Neu1 sialidase and matrix metalloproteinase-9 cross-talk regulates nucleic acid-induced endosomal TOLL-like receptor-7 and -9 activation, cellular signaling and pro-inflammatory responses. Cellular Signalling 25: 2093\u20132105","journal-title":"Cellular Signalling"},{"key":"8_CR153","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.cellsig.2014.02.015","volume":"26","author":"F Alghamdi","year":"2014","unstructured":"Alghamdi F, Guo M, Abdulkhalek S et al (2014) A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes. Cellular Signalling 26: 1355\u20131368","journal-title":"Cellular Signalling"},{"key":"8_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23937\/2377-3634\/1410005","volume":"1","author":"F Haxho","year":"2014","unstructured":"Haxho F, Alghamdi F, Neufeld RJ et al (2014) Novel Insulin Receptor-Signaling Platform. Int J Diabetes Clin Res 1:1-10","journal-title":"Int J Diabetes Clin Res"},{"key":"8_CR155","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cellsig.2017.12.006","volume":"43","author":"F Haxho","year":"2018","unstructured":"Haxho F, Haq S, Szewczuk MR (2018) Biased G protein-coupled receptor agonism mediates Neu1 sialidase and matrix metalloproteinase-9 crosstalk to induce transactivation of insulin receptor signaling. Cellular Signalling 43: 71\u201384","journal-title":"Cellular Signalling"},{"key":"8_CR156","doi-asserted-by":"publisher","first-page":"40860","DOI":"10.18632\/oncotarget.8396","volume":"7","author":"F Haxho","year":"2016","unstructured":"Haxho F, Neufeld RJ, Szewczuk MR (2016) Neuraminidase-1: A novel therapeutic target in multistage tumorigenesis. Oncotarget 7: 40860\u201340881","journal-title":"Oncotarget"},{"key":"8_CR157","first-page":"4573","volume":"9","author":"M Hrynyk","year":"2015","unstructured":"Hrynyk M, Ellis JP, Haxho F et al (2015) Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma. Drug Des Devel Ther 9:4573\u20134586","journal-title":"Drug Des Devel Ther"},{"key":"8_CR158","unstructured":"O\u2019Shea LK, Abdulkhalek S, Allison S, Neufeld RJ, Szewczuk MR (2014) Therapeutic target-ing of Neu1 sialidase with oseltamivir phosphate (Tamiflu(R)) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. Oncotarget Ther 7:117\u2013 134"},{"key":"8_CR159","doi-asserted-by":"crossref","unstructured":"Abdulkhalek S, Geen OD, Brodhagenn L, Haxho F et al (2014) Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma. Clinical and Translational Medicine 3: 1-28","DOI":"10.1186\/s40169-014-0028-z"},{"key":"8_CR160","unstructured":"Haxho F, Allison S, Alghamdi F et al (2014) Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma. Breast Cancer Targets Ther 6:191\u2013203"},{"key":"8_CR161","unstructured":"Abdulkhalek S, Hrynyk M, Szewczuk MR (2013) A novel G-protein-coupled receptorsignaling platform and its targeted translation in human disease. Res Rep Biochem 3:17\u201330"}],"container-title":["Advances in Experimental Medicine and Biology","Breast Cancer Metastasis and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-20301-6_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T14:44:26Z","timestamp":1664203466000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-20301-6_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030203009","9783030203016"],"references-count":161,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-20301-6_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"28 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}